Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.81 USD
Change Today -0.02 / -0.52%
Volume 100.0K
SKBI On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

skystar bio-pharmaceutical (SKBI) Snapshot

Open
$3.83
Previous Close
$3.83
Day High
$3.89
Day Low
$3.75
52 Week High
07/3/14 - $8.22
52 Week Low
03/16/15 - $3.62
Market Cap
33.1M
Average Volume 10 Days
42.0K
EPS TTM
$1.33
Shares Outstanding
8.7M
EX-Date
--
P/E TM
2.9x
Dividend
--
Dividend Yield
--
Current Stock Chart for SKYSTAR BIO-PHARMACEUTICAL (SKBI)

Related News

No related news articles were found.

skystar bio-pharmaceutical (SKBI) Related Businessweek News

No Related Businessweek News Found

skystar bio-pharmaceutical (SKBI) Details

Skystar Bio-Pharmaceutical Company researches, develops, produces, markets, and sells veterinary healthcare and medical care products in the People’s Republic of China. The company offers micro-organism products, veterinary medicines for poultry and livestock, feed additives, and bio-pharmaceutical veterinary vaccines. It markets its products through distributers and franchise distributors, as well as directly to customers. The company is headquartered in Xi’an, the People’s Republic of China.

skystar bio-pharmaceutical (SKBI) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $121.6K
Chief Financial Officer
Total Annual Compensation: $182.5K
Compensation as of Fiscal Year 2013.

skystar bio-pharmaceutical (SKBI) Key Developments

Skystar Bio-Pharmaceutical Company Announces Receipt Of Nasdaq Non-Compliance Letter Due To Delay In Filing Form 10-K

Skystar Bio-Pharmaceutical Company announced that the Company received a notification from the Nasdaq Stock Market (Nasdaq) informing the Company that since it had not filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2014, the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1). The Nasdaq notification letter does not result in the immediate delisting of the Company’s common stock, and the stock will continue to trade uninterrupted under its current trading symbol. The Company must submit a plan of compliance with the foregoing listing deficiency by no later than June 15, 2015. If its plan is approved by the Nasdaq staff, the Company may be eligible for a listing exception of up to 180 calendar days or until October 12, 2015 to regain compliance. If the Nasdaq staff concludes that the Company will not be able to cure the deficiency, or if the Company determines not to submit the required materials or make the required representations, the Company's common stock will be subject to delisting by Nasdaq. The Company expects the completion of the 2014 audit and filing of the 2014 Annual Report by the end of May 2015, but in no event later than the Plan of Compliance Deadline.

Skystar Bio Pharmaceutical Company announced delayed annual 10-K filing

On 04/01/2015, Skystar Bio Pharmaceutical Company announced that they will be unable to file their next 10-K by the deadline required by the SEC.

Skystar Bio Pharmaceutical Company Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Reiterates Earnings Guidance for the Fiscal 2014

Skystar Bio Pharmaceutical Company announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported revenue of $18,352,693 against $15,992,408 a year ago. Income from operations was $5,399,574 against $4,737,701 a year ago. Net income was $4,909,453 against $3,734,197 a year ago. Income before provision for income taxes was $5,622,387 against $4,516,174 a year ago. Diluted earnings per share were $0.57 against basic and diluted earnings per share of $0.49 a year ago. For the nine months, the company reported revenue of $39,424,886 against $32,858,294 a year ago. Income from operations was $9,939,652 against $10,354,234 a year ago. Net income was $8,695,663 against $8,197,811 a year ago. Income before provision for income taxes was $10,521,013 against $9,997,829 a year ago. Diluted earnings per share were $1.08 against basic and diluted earnings per share of $1.08 a year ago. Net cash provided operating activities was $15,244,465 against net cash used in operating activities of $9,092,042 a year ago. Purchases of property, plant and equipment were $8,645 against $9,290 a year ago. The company reiterated its fiscal 2014 guidance to be in the range of $46 million to $50 million for the full year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SKBI:US $3.81 USD -0.02

SKBI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
China Animal Husbandry Industry Co Ltd CNY24.82 CNY -0.18
Guangdong VTR Bio-Tech Co Ltd CNY41.09 CNY 0.00
Inner Mongolia Jinyu Group Ltd CNY61.19 CNY +1.39
Xinjiang Tecon Animal Husbandry Bio-Technology Co Ltd CNY21.52 CNY +0.72
View Industry Companies
 

Industry Analysis

SKBI

Industry Average

Valuation SKBI Industry Range
Price/Earnings 2.8x
Price/Sales 0.7x
Price/Book 0.3x
Price/Cash Flow 3.0x
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SKYSTAR BIO-PHARMACEUTICAL, please visit www.skystarbio-pharmaceutical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.